Press Releases

Apr 15

Solid Biosciences Announces Upcoming Preclinical Data Presentations at The American Society of Gene and Cell Therapy Annual Meeting

CAMBRIDGE, Mass. , April 15, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that preclinical data from its gene therapy program for Duchenne muscular dystrophy (DMD) will be presented at the 22 nd Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)

Read More
Mar 13

Solid Biosciences Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update

–Activities underway to commence dosing of second cohort of patients in the IGNITE DMD clinical trial at 2E14 vg/kg of SGT-001– CAMBRIDGE, Mass. , March 13, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today reported financial results for the fourth quarter and fiscal year ended

Read More
Feb 07

Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy

- Company expediting planned dose escalation activities - - Low levels of SGT-001 microdystrophin protein detected at the starting dose - - Conference call to be held at 8:30 a.m. ET today - CAMBRIDGE, Mass. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences (Nasdaq: SLDB) announced today

Read More
Jan 02

Solid Biosciences to Present at the J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Ilan Ganot , Co-Founder, Chief Executive Officer and President of Solid Biosciences will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9 th at 7:30 am

Read More

News & Events

Press Releases

Solid Biosciences Announces Upcoming Preclinical Data Presentations at The American Society of Gene and Cell Therapy Annual Meeting

Solid Biosciences Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update

Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy

Solid Biosciences to Present at the J.P. Morgan Healthcare Conference